Skip to main content

Table 2 Primary and secondary outcomes of the included trials: PCT arms versus control arms

From: Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis

Study (year)Primary endpointsSecond endpoints
28-day mortalityduration of antibiotic therap by for the first episode of infectiona length of hospitalizationa mortality in hospitalizationtotal duration of antibiotic therapy a length of ICU stay a Recurrences
Svoboda (2007) [33]10/13NANANANA16.1 (6.9) /19.4 (8.9)NA
Nobre (2008) [32]8/86.0 (7.8) /9.5 (7.8)17.0 (23.3) /23.5 (9.8)9/9/8.0 (5.8) /14.0 (8.3)4.0 (5.0) /7.0 (22.5)1/1/
Hochreiter (2009) [31]NA5.9 (1.7) /7.9 (0.5)NA15/145.9 (1.7) /7.9 (0.5)15.5 (12.5) /17.7 (10.1)NA
Schroeder (2009) [30]NA6.6 (1.1) /8.3 (0.7)NA3/36.6 (1.1) /8.3 (0.8)16.4 (8.3) /16.7 (5.6)NA
Stolz (2009) [29]8/123.0 (2.0) /5.0 (4.1)26.0 (10.4) /26.0 (4.1)10/1410.0 (2.5) /15.0 (3.3)NA6/11
Bouadma (2010) [28]65/646.1 (6.0) /9.9 (7.1)26.1 (19.3) /26.4 (18.3)NA10.3 (7.7) /13.3 (7.6)15.9 (16.1) /14.4 (4.1)20/16
Layios (2012) [26]56/53NANANANA7.0 (8.9) /7.0 (10.4)NA
Jensen (2011) [27]190/191NANANANA6.0 (6.7) /5.0 (5.9)NA
Liu (2013) [23]6/58.1 (0.3) /9.3 (0.3)27.0 (4.9) /32.0 (5.4)NA8.1 (0.3) /9.3 (0.3)12.0 (2.9) /14.0 (2.7)3/1
Annane (2013) [25]NANA27.0 (29.6) /33.0 (43.0)7/10NA22.0 (25.2) /23.0 (37.0)NA
Deliberato (2013) [24]NANA11.0 (11) /11.0 (56.5)2/4NA3.5 (14.0) /3.0 (6.8)2/1
Shehabi (2014) [22]21/15NA15.0 (14.8) /17.0 (16.3)30/26NA6.0 (4.8) /6.0 (4.4)6/12
Najafi (2015) [21]NANA20.0 (9.0) /22.0 (14.8)5/4NA4.0 (4.5) /6.0 (6.5)NA
Jong (2016) [18]149/196NA22.0 (19.3) /22.0 (20.7)NANA8.5 (8.9) /9.0 (9.6)38/23
Bloos (2016) [20]77/607.0 (6.7) /7.0 (7.4)29.0 (23.7) /29.0 (24.4)NANA12.0 (14.1) /12.0 (11.1)NA
  1. aMean (SD); NA, not available